[go: up one dir, main page]

CA2116130A1 - Diagnostic et traitement de la maladie de parkinson - Google Patents

Diagnostic et traitement de la maladie de parkinson

Info

Publication number
CA2116130A1
CA2116130A1 CA002116130A CA2116130A CA2116130A1 CA 2116130 A1 CA2116130 A1 CA 2116130A1 CA 002116130 A CA002116130 A CA 002116130A CA 2116130 A CA2116130 A CA 2116130A CA 2116130 A1 CA2116130 A1 CA 2116130A1
Authority
CA
Canada
Prior art keywords
disease
mao
parkinson
individual
haplotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002116130A
Other languages
English (en)
Inventor
Xandra O. Breakefield
Gokhan S. Hotamisligil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CA2116130A1 publication Critical patent/CA2116130A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y104/00Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03004Monoamine oxidase (1.4.3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002116130A 1991-09-20 1992-08-17 Diagnostic et traitement de la maladie de parkinson Abandoned CA2116130A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76230291A 1991-09-20 1991-09-20
US07/762,302 1991-09-20

Publications (1)

Publication Number Publication Date
CA2116130A1 true CA2116130A1 (fr) 1993-04-01

Family

ID=25064666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116130A Abandoned CA2116130A1 (fr) 1991-09-20 1992-08-17 Diagnostic et traitement de la maladie de parkinson

Country Status (5)

Country Link
EP (1) EP0666745A4 (fr)
JP (1) JPH07501518A (fr)
AU (1) AU2492192A (fr)
CA (1) CA2116130A1 (fr)
WO (1) WO1993005783A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783680A (en) * 1993-10-06 1998-07-21 The General Hospital Corporation Genetic diagnosis and treatment for impulsive aggression
WO2002010454A2 (fr) * 2000-07-28 2002-02-07 Genaissance Pharmaceuticals, Inc. Haplotypes du gene alas2? ¿
WO2002012561A2 (fr) * 2000-08-03 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene or1g1
WO2002012498A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene isl1
WO2002012499A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene ntf3
WO2002012342A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene edg4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030570A (en) * 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
WO1991018005A1 (fr) * 1990-05-14 1991-11-28 Duke University Genes clones codant pour le recepteur de dopamine d¿1?

Also Published As

Publication number Publication date
WO1993005783A1 (fr) 1993-04-01
JPH07501518A (ja) 1995-02-16
EP0666745A1 (fr) 1995-08-16
AU2492192A (en) 1993-04-27
EP0666745A4 (fr) 1995-10-25

Similar Documents

Publication Publication Date Title
Comings et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse
Gutiérrez et al. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder
US20030044797A1 (en) Detection of CYP2D6 polymorphisms
Ozelius et al. Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism
Comings Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene
Hamilton et al. Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder
Souery et al. Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes
Kramer et al. A locus for the nystagmus-associated form of episodic ataxia maps to an 11-cM region on chromosome 19p
KR20000052680A (ko) 후발성 진성 당뇨병으로 분리되는 미토콘드리아성 dna돌연변이
Maier-Dobersberger et al. Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis
US20060088874A1 (en) Methods and kits for detecting mutations
US20040248092A1 (en) Methods of screening for parkinsons's disease
Bandmann et al. Mitochondrial DNA polymorphisms in pathologically proven Parkinson’s disease
Geijer et al. Tyrosine hydroxylase and dopamine D4 receptor allelic distribution in Scandinavian chronic alcoholics
Nanko et al. No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms
Körner et al. RFLP alleles at the tyrosine hydroxylase locus: no association found to affective disorders
Girmen et al. Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus
CA2116130A1 (fr) Diagnostic et traitement de la maladie de parkinson
Schuback et al. Screen for MAOA mutations in target human groups
Nimgaonkar et al. Negative association of schizophrenia with HLA DQB1* 0602: evidence from a second African-American cohort
Bonneau et al. No evidence of genetic heterogeneity in dominant optic atrophy.
Nurnberger Jr et al. Chromosome 6 workshop report
Nanko et al. Linkage studies between affective disorder and dopamine D2, D3, and D4 receptor gene loci in four Japanese pedigrees
Balciuniene et al. Linkage analysis of candidate loci in families with recurrent major depression
US20030054381A1 (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases

Legal Events

Date Code Title Description
FZDE Dead